Evidence-Based Cardiovascular Disease Medicines' Availability in Low-Cost Generic Drug Programs in the United States : A Cross-Sectional Study

CONCLUSION: Coverage of evidence-based medications for the 6 CVDs investigated varied by LCGP and condition. Because high availability of core CVD pharmacotherapy can enhance optimal disease state management, LCGPs should identify existing limitations in their coverage and continuously revise their formularies to improve the comprehensiveness of CVD medication coverage.PRIMARY FUNDING SOURCE: None.PMID:37665997 | DOI:10.7326/M23-0287

Source: Annals of Internal Medicine - September 4, 2023 Category: Internal Medicine Authors: Ivy T Ton Jungyeon Moon Anthony Sengul Freny Vaghaiwalla Mody Towhid Rahman Janet K Han Cynthia A Jackevicius Source Type: research